• Nintedanib (BIBF 1120): Optimizing Antiangiogenic Workflows

  2026-07-29

  Nintedanib (BIBF 1120) enables precise, reproducible inhibition of VEGFR, PDGFR, and FGFR signaling, directly supporting advanced cancer and fibrosis models. This guide distills evidence-backed protocols, troubleshooting insights, and practical assay tips—especially for ATRX-deficient tumor research.

• Shufeng Xingbi Therapy Restores Immunity and Microbiota in A

  2026-07-29

  This study investigates the ability of Shufeng Xingbi Therapy (SFXBT) to rebalance Th1/Th2 immune responses and modulate intestinal flora in a rat model of allergic rhinitis. The findings reveal mechanistic links between immune modulation, microbial composition, and the mitigation of allergic symptoms, providing a basis for future translational research.

• DiscoveryProbe FDA-approved Drug Library: Transforming Drug

  2026-07-28

  The DiscoveryProbe FDA-approved Drug Library empowers researchers with 2,320 pre-dissolved clinical compounds, streamlining high-throughput screens for drug repositioning and target identification. Its robust format and regulatory validation enable rapid, reliable experimental workflows, as demonstrated in cutting-edge oncology and neurodegenerative disease studies.

• Maternal KLF17 Orchestrates Zygotic Genome Activation in Mic

  2026-07-28

  Hu et al. (2024) uncover maternal KLF17 as a key regulator of zygotic genome activation (ZGA) via RNA Pol II recruitment in early mouse embryos. By leveraging translational inhibition and proteomic analysis, the study clarifies how maternal transcription factors drive embryonic genome activation, offering new avenues for studying developmental regulation.

• Auranofin: Thioredoxin Reductase Inhibitor for Redox Biology

  2026-07-27

  Auranofin empowers researchers to dissect redox homeostasis, radiosensitization, and apoptosis by precisely targeting thioredoxin reductase. Its robust performance across cancer and antimicrobial models, combined with actionable workflow optimizations, makes it an invaluable asset for advanced experimental design.

• Biotin-HPDP in Immuno-Oncology: Precision Tools for PD-L1 Pa

  2026-07-27

  Explore how Biotin-HPDP enables advanced thiol-specific protein labeling to dissect PD-L1 regulation and immune checkpoint biology in cancer. This article uniquely bridges redox proteomics with immuno-oncology assay innovation.

• SGI-1027: DNA Methyltransferase Inhibitor for Epigenetic Con

  2026-07-26

  SGI-1027 is a robust DNA methyltransferase inhibitor enabling precise control over epigenetic states in cancer research. Its dual-action mechanism supports high-confidence tumor suppressor gene reactivation and workflow flexibility, setting it apart for both foundational studies and advanced translational applications.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix-T

  2026-07-25

  This study establishes 'testosterone bounce'—a transient rise in serum testosterone above 20 ng/dL during GnRH antagonist therapy—as a promising biomarker for favorable overall and cancer-specific survival in prostate cancer patients treated with degarelix. These findings advance the precision of prognostic monitoring beyond PSA levels and traditional androgen deprivation endpoints.

• Optimizing Epigenetic Modulation: Practical Insights with RG

  2026-07-24

  This article addresses the most common laboratory challenges in epigenetic gene regulation and cell-based assays by providing scenario-driven guidance on the use of RG108 (SKU A1913), a small-molecule DNA methyltransferase inhibitor. Drawing from validated protocols and quantitative data, it equips biomedical researchers and lab technicians with actionable solutions for reproducibility, data interpretation, and reliable vendor selection. Explore how RG108 from APExBIO supports high-fidelity experimental outcomes.

• PCMT1 Drives Ovarian Cancer Metastasis via Anoikis Resistanc

  2026-07-24

  Zhang et al. employed a genome-wide CRISPR/Cas9 knockout screen to identify PCMT1 as a pivotal factor in ovarian cancer metastasis by promoting resistance to anoikis and enhancing tumor cell-ECM interactions. These findings highlight PCMT1 as a promising therapeutic target and advance understanding of mechanisms underlying metastatic progression.

• KPT330 Enhances Cas9 Specificity by Modulating mRNA Nuclear

  2026-07-23

  The reference study reveals that KPT330, an FDA-approved SINE compound, indirectly regulates CRISPR-Cas9 activity by inhibiting Cas9 mRNA nuclear export, thereby improving genome and base editing specificity in human cells. This mechanistic insight advances strategies for reducing off-target effects in genome editing applications.

• Driving CRISPR Precision: Mechanistic Levers in Cas9 mRNA De

  2026-07-23

  This thought-leadership article explores how advanced mRNA engineering—exemplified by EZ Cap™ Cas9 mRNA (m1Ψ)—transforms CRISPR-Cas9 genome editing in mammalian cells. Bridging mechanistic insights, recent peer-reviewed evidence on mRNA nuclear export, and practical strategies, we map a new framework for translational researchers seeking maximum genome editing fidelity, efficiency, and safety. With a critical view of evolving competitive solutions, we outline how next-generation capped Cas9 mRNA tools reshape the landscape, providing translational teams with actionable guidance and a vision for the future.

• SGI-1027 Downregulates DNMT1 to Restore RB1 in Gastric Cance

  2026-07-22

  This study demonstrates that SGI-1027, a DNA methyltransferase inhibitor, suppresses gastric cancer cell growth and metastasis by downregulating DNMT1 and reactivating the RB1 tumor suppressor gene. These findings provide mechanistic insight into epigenetic modulation as a therapeutic strategy for gastric cancer.

• Ceftazidime in Research: Optimizing Third-Generation Cephalo

  2026-07-22

  Ceftazidime stands out as a third-generation cephalosporin for robust modeling of Gram-negative bacterial infection, especially with multidrug-resistant Pseudomonas aeruginosa. This article delivers actionable insights for maximizing experimental reproducibility, from protocol fine-tuning to advanced troubleshooting in resistance-prone assays.

• Ibuprofen’s Mechanistic Impact: From COX Inhibition to Trans

  2026-07-21

  This thought-leadership article explores the dual COX inhibition and anti-proliferative mechanisms of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid), highlighting its relevance in colon cancer research and translational workflows. By integrating mechanistic insights, protocol guidance, and the evolving landscape of drug-protein interactions, we deliver strategic recommendations for researchers aiming to bridge preclinical findings to clinical impact. The discussion leverages APExBIO’s high-purity Ibuprofen and recent molecular recognition studies to set a new benchmark for evidence-driven experimental design.

553 records 10/37 page Previous Next First page 上5页 678910 下5页 Last page